Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial
Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial
AST's PCOP and TCC COP welcome Drs. Daly, Chen, and Kobashigawa to discuss the safety and efficacy of everolimus combined with low-dose tacrolimus to prevent major adverse transplant events (MATEs) in children after heart transplant.
- 2:00 PM - 3:00 PM EST
- Virtual
"Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial"
(JAMA. 2025 Oct 21;334(15):1339-1348. doi: 10.1001/jama.2025.14338.)
In this article:
[Through a] multicenter, randomized, open-label, clinical trial [the authors sought to] evaluate the safety and efficacy of everolimus combined with low-dose tacrolimus to prevent major adverse transplant events (MATEs) in children after heart transplant. [Based on this trial,] among 6-month pediatric heart transplant survivors, everolimus and low-dose tacrolimus did not differ from tacrolimus and mycophenolate in preventing the composite of cellular rejection, CAV, and CKD at 30 months. However, everolimus and low-dose tacrolimus appear to be safe based on the total burden of 6 MATEs and may be associated with improved kidney function and less CMV infection. Read more.
Speaker:
Kevin P. Daly, MD • Boston Children's Hospital, Boston, MA
Moderator:
Justin Chen, PharmD • Children's Healthcare of Atlanta, Atlanta, GA
Discussant:
Jon Kobashigawa, MD, FAST • Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
This AST Journal Club Series webinar is hosted by AST's Pediatric Community of Practice (PCOP) and supported by the Thoracic and Critical Care Community of Practice (TCC COP). All AST Journal Clubs are free but registration is required to attend live.
Advertisements
